Screener
ADMA Biologics ADMA Business Acquisitions Pro Forma Revenue
Business Acquisitions Pro Forma Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:BusinessAcquisitionsProFormaRevenue.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| (in thousands) | ADMA Bio Manufacturing | Plasma Collection Centers | Total |
|---|---|---|---|
| Reconciliation of revenues: | |||
| Segment revenue | $124,360 | ||
| License revenue | 35 | ||
| Consolidated revenues | $124,395 | ||
| Reconciliation of selling, general and administrative expense: | |||
| Segment selling, marketing and distribution expense | $7,634 | ||
| Segment general and administrative expense | 8,340 | ||
| Corporate general and administrative expense (a) | 10,763 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's business acquisitions pro forma revenue?
- ADMA Biologics (ADMA) reported business acquisitions pro forma revenue of $124.4M in Q2 2026.
- What does business acquisitions pro forma revenue mean?
- Business Acquisitions Pro Forma Revenue
Ask your AI about ADMA Biologics's business acquisitions pro forma revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude